You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 绿叶制药涨逾3% 两大核心产品获推荐
格隆汇 09-17 10:21
格隆汇9月17日丨绿叶制药(2186.HK)现报6.39港元,涨3.4%,暂成交2658万港元,最新总市值208亿港元。绿叶制药昨日(16日)晚间发公告称,由三大权威学术机构共同制定的《中国食管癌放射治疗指南(2019版)》于近期发布,绿叶制药的两大核心产品——创新制剂紫杉醇脂质体(力扑素®)、1类创新药注射用甘氨双唑钠(希美纳®)作为推荐用药,同时入选该指南。公司管理层表示:“此次获得推荐,将进一步提升这两个产品在相关适应症上的更广泛应用,有效提升患者的用药可及性,使更多患者获益。”天风证券曾发研报指,绿叶制药半年报业绩强劲增长,中期归母净利润7.67亿元人民币,同比增长36.2%,在研管线蓄势待发,维持“增持”评级。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account